IDH1 and central nervous system cancer: Two early phase clinical trials combining anti-PD1 checkpoint inhibitors with azacytidine (DNA methyltransferase inhibitor) or vorinostat (HDAC inhibitor) plus standard chemoradiation are currently underway in IDH-mutant gliomas (NCT03684811) and newly diagnosed GBM (NCT03426891), respectively.